NovoRapid 100 units/ml solution for injection in vial

DRUG4 trials

Sponsors

University Hospital Maastricht, Amsterdam UMC, Centre Hospitalier Universitaire De Nantes, Medical University Of Graz

Conditions

Heart failure with preserved ejection fractionHyperkalemiaType 2 Diabetes MellitusUnequivocal epicardial and/or microvascular vasospastic angina

Phase 1

A single-center pilot study to establish a novel hypoglycemic clamp procedure to assess the time to spontaneous recovery from hypoglycemia in people with and without diabetes

CompletedCTIS2025-520996-16-00

Medical University Of GrazType 2 Diabetes Mellitus

Start: 2025-07-02End: 2025-11-07Target: 24Updated: 2025-06-11

Phase 2

Vericiguat in Vasospastic Angina (ViVA)

RecruitingCTIS2022-502998-42-00

Amsterdam UMCUnequivocal epicardial and/or microvascular vasospastic angina

Start: 2025-02-10Target: 55Updated: 2026-01-21

Phase 4

The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction

CompletedCTIS2022-501682-45-00

University Hospital MaastrichtHeart failure with preserved ejection fraction

Start: 2023-02-13End: 2024-12-01Target: 48Updated: 2022-12-01

InSaKa trial: Insulin dextrose infusion versus nebulized salbutamol versus combination of salbutamol and insulin dextrose in acute hyperkalemia: a randomized clinical trial

CompletedCTIS2024-514889-40-00

Centre Hospitalier Universitaire De NantesHyperkalemia

Start: 2019-12-20End: 2025-12-20Target: 525Updated: 2024-07-19